dc.contributor.author
Haase, Katharina
dc.contributor.author
Piwonski, Iris
dc.contributor.author
Stromberger, Carmen
dc.contributor.author
Thieme, Nadine
dc.contributor.author
Heiland, Max
dc.contributor.author
Beck-Broichsitter, Benedicta
dc.contributor.author
Hofmann, Veit M.
dc.contributor.author
Kofla, Grzegorz
dc.contributor.author
Sander, Steffen
dc.contributor.author
Keilholz, Ullrich
dc.contributor.author
Neumann, Konrad
dc.contributor.author
Stölzel, Katharina
dc.contributor.author
Olze, Heidi
dc.contributor.author
Arens, Philipp
dc.contributor.author
Dommerich, Steffen
dc.contributor.author
Coordes, Annekatrin
dc.date.accessioned
2023-07-31T13:45:24Z
dc.date.available
2023-07-31T13:45:24Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/40289
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-40010
dc.description.abstract
Purpose: The aim was to analyze the incidence and survival of patients living with HIV (PLWH) with head and neck squamous cell carcinoma (HNSCC) and to compare with a control group of HIV-negative HNSCC patients.
Methods: Clinicopathological data and predictors for overall survival (OS) and disease-free survival (DFS) were investigated (2009-2019).
Results: 50 of 5151 HNSCC patients (0.97%) were PLWH, and 76% were smokers. Age <= 60 years, HIV-PCR <= 50 copies, CD4 cells <= 200/mm(3), cART treatment, T and UICC classification, oral cavity and nasal/paranasal sinuses, and therapy were significantly associated with OS in univariate analysis. In the multivariate analysis, only age and HIV-PCR independently predicted OS. The OS of the 50 PLWH was not significantly altered compared with the 5101 HIV-negative controls. However, OS and DFS were significantly inferior in advanced tumor stages of PLWH compared with an age-matched control group of 150 HIV-negative patients.
Conclusions: PLWH were diagnosed with HNSCC at a significantly younger age compared to HIV-negative patients. Taking into account patient age at initial diagnosis, both OS and DFS rates in PLWH are significantly worse compared with a matched control group of HIV-negative patients in advanced tumor stages UICC III/IV. The prognosis (OS) is improved when taking cART treatment, the HIV viral load is undetectable and CD4 count is high.
en
dc.rights.uri
https://creativecommons.org/licenses/by/4.0/
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
dc.title
Incidence and survival of HNSCC patients living with HIV compared with HIV-negative HNSCC patients
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.doi
10.1007/s00405-020-06573-9
dcterms.bibliographicCitation.journaltitle
European Archives of Oto-Rhino-Laryngology
dcterms.bibliographicCitation.number
10
dcterms.bibliographicCitation.originalpublishername
Springer Nature
dcterms.bibliographicCitation.pagestart
3941
dcterms.bibliographicCitation.pageend
3953
dcterms.bibliographicCitation.volume
278
refubium.affiliation
Charité - Universitätsmedizin Berlin
refubium.funding
Springer Nature DEAL
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.bibliographicCitation.pmid
33492419
dcterms.isPartOf.issn
0937-4477
dcterms.isPartOf.eissn
1434-4726